Abzena to build US biologics manufacturing plant in North Carolina

New facility will be research partnering company’s sixth global site and will be dedicated to mammalian biologics

The company announced it was adding a sixth global site in January. The new plant – which will cost over $200 million and will be equipped with 12 X 2000L bioreactors -- will be dedicated to cGMP manufacturing capacity for mammalian biologics.

Abzena said the design of the facility has been optimized for phase III and commercial manufacturing of biologics.

As a result of the project’s phased approach to construction, four modular suites will initially come online, each including up to two 2000L bioreactors before two further 2000L suites are added. 

Additionally, the site will be equipped to handle existing and new advances in manufacturing such as continuous manufacturing and perfusion.  Manufacturing is expected to start in mid-2022.

“We are pleased to provide integrated asset development with a full suite of in-house services from discovery through clinical and commercial phases without the need for technology transfer,” said Jonathan Goldman, CEO of Abzena in a statement.